A A+ A A A


Area 2

Projects in Area 2 consider the main issues of cancer heterogeneity (genetic instability, tumor micro-environment, tumorigenic cancer stem cells), cancer progression and metastases, intrinsic therapeutic resistance and acquired resistance of cancer.

  • CTCs for disease monitoring
  • Tracking the trace
  • Blood based cancer diagnostics
  • Minimal residual disease
  • Eukaryotic initiation factors
  • Induced apoptosis
  • ADX models


Research projects

CBmed Projects aim to develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, better therapy monitoring and a more personalized treatment of patients.


Contact Person

Assoz. Prof. Dr. Armin Gerger
Scientific Leader Area 2

Most projects cover the full workflow from identification to validation up to the translation of cancer biomarkers into clinical use. Liquid biopsy as a minimally invasive method to access circulating tumor cells and circulating cell free nucleic acids is a major focus of Area 2, with the aim to develop refined selection and detection methodologies which result in the generation of new predictive and prognostic biomarkers in this research field.

Projects of Area 2 are using data and technology platforms provided in Area 1 and the tight link to research questions regarding inflammation and metabolism in Area 3 will guarantee a more comprehensive view on biomarker research with respect to tumor immunology.